vs
LXP Industrial Trust（LXP）与VERACYTE, INC.（VCYT）财务数据对比。点击上方公司名可切换其他公司
VERACYTE, INC.的季度营收约是LXP Industrial Trust的1.6倍（$140.6M vs $86.7M），LXP Industrial Trust净利率更高（33.2% vs 29.3%，领先3.9%），VERACYTE, INC.同比增速更快（18.5% vs -14.0%），过去两年VERACYTE, INC.的营收复合增速更高（20.5% vs 0.3%）
LXP工业信托是一家公开上市的房地产投资信托，专注于持有、运营和投资美国核心市场的优质工业地产，主要涵盖配送中心、物流设施及轻型工业物业，服务电商、第三方物流、先进制造等领域租户，为投资者创造长期稳定收益。
Veracyte是一家领先的分子诊断企业，专注开发专有的基因组检测方案，可实现癌症及其他复杂疾病的早期精准检测，产品服务于医疗机构以优化临床决策，核心市场位于美国，正稳步拓展全球业务布局。
LXP vs VCYT — 直观对比
营收规模更大
VCYT
是对方的1.6倍
$86.7M
营收增速更快
VCYT
高出32.5%
-14.0%
净利率更高
LXP
高出3.9%
29.3%
两年增速更快
VCYT
近两年复合增速
0.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $86.7M | $140.6M |
| 净利润 | $28.8M | $41.1M |
| 毛利率 | 81.5% | 72.5% |
| 营业利润率 | 34.6% | 26.4% |
| 净利率 | 33.2% | 29.3% |
| 营收同比 | -14.0% | 18.5% |
| 净利润同比 | — | 704.8% |
| 每股收益（稀释后） | — | $0.50 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LXPVCYT
| Q4 25 | $86.7M | $140.6M | ||
| Q3 25 | $86.9M | $131.9M | ||
| Q2 25 | $87.7M | $130.2M | ||
| Q1 25 | $88.9M | $114.5M | ||
| Q4 24 | $100.9M | $118.6M | ||
| Q3 24 | $85.6M | $115.9M | ||
| Q2 24 | $85.8M | $114.4M | ||
| Q1 24 | $86.3M | $96.8M |
净利润LXPVCYT
| Q4 25 | $28.8M | $41.1M | ||
| Q3 25 | $36.3M | $19.1M | ||
| Q2 25 | $29.1M | $-980.0K | ||
| Q1 25 | $19.0M | $7.0M | ||
| Q4 24 | — | $5.1M | ||
| Q3 24 | $6.3M | $15.2M | ||
| Q2 24 | $5.4M | $5.7M | ||
| Q1 24 | $-269.0K | $-1.9M |
毛利率LXPVCYT
| Q4 25 | 81.5% | 72.5% | ||
| Q3 25 | 82.3% | 69.2% | ||
| Q2 25 | 81.9% | 69.0% | ||
| Q1 25 | 80.7% | 69.5% | ||
| Q4 24 | 85.3% | 66.4% | ||
| Q3 24 | 82.5% | 68.2% | ||
| Q2 24 | 82.0% | 68.1% | ||
| Q1 24 | 82.4% | 64.5% |
营业利润率LXPVCYT
| Q4 25 | 34.6% | 26.4% | ||
| Q3 25 | 50.4% | 17.4% | ||
| Q2 25 | 33.7% | -4.0% | ||
| Q1 25 | 21.8% | 2.5% | ||
| Q4 24 | — | 3.5% | ||
| Q3 24 | 7.9% | 10.4% | ||
| Q2 24 | 6.9% | 4.0% | ||
| Q1 24 | 1.0% | -4.8% |
净利率LXPVCYT
| Q4 25 | 33.2% | 29.3% | ||
| Q3 25 | 41.7% | 14.5% | ||
| Q2 25 | 33.2% | -0.8% | ||
| Q1 25 | 21.4% | 6.2% | ||
| Q4 24 | — | 4.3% | ||
| Q3 24 | 7.4% | 13.1% | ||
| Q2 24 | 6.3% | 5.0% | ||
| Q1 24 | -0.3% | -1.9% |
每股收益（稀释后）LXPVCYT
| Q4 25 | — | $0.50 | ||
| Q3 25 | $0.12 | $0.24 | ||
| Q2 25 | $0.09 | $-0.01 | ||
| Q1 25 | $0.06 | $0.09 | ||
| Q4 24 | — | $0.07 | ||
| Q3 24 | $0.02 | $0.19 | ||
| Q2 24 | $0.01 | $0.07 | ||
| Q1 24 | $-0.01 | $-0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $170.4M | $362.6M |
| 总债务越低越好 | $1.4B | — |
| 股东权益账面价值 | $2.0B | $1.3B |
| 总资产 | $3.5B | $1.4B |
| 负债/权益比越低杠杆越低 | 0.66× | — |
8季度趋势，按日历期对齐
现金及短期投资LXPVCYT
| Q4 25 | $170.4M | $362.6M | ||
| Q3 25 | $229.7M | $315.6M | ||
| Q2 25 | $71.0M | $219.5M | ||
| Q1 25 | $70.9M | $186.1M | ||
| Q4 24 | $101.8M | $239.1M | ||
| Q3 24 | $55.0M | $274.1M | ||
| Q2 24 | $48.7M | $235.9M | ||
| Q1 24 | $293.8M | $209.2M |
总债务LXPVCYT
| Q4 25 | $1.4B | — | ||
| Q3 25 | $1.5B | — | ||
| Q2 25 | $1.5B | — | ||
| Q1 25 | $1.5B | — | ||
| Q4 24 | $1.6B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益LXPVCYT
| Q4 25 | $2.0B | $1.3B | ||
| Q3 25 | $2.1B | $1.3B | ||
| Q2 25 | $2.1B | $1.2B | ||
| Q1 25 | $2.1B | $1.2B | ||
| Q4 24 | $2.1B | $1.2B | ||
| Q3 24 | $2.1B | $1.2B | ||
| Q2 24 | $2.1B | $1.1B | ||
| Q1 24 | $2.2B | $1.1B |
总资产LXPVCYT
| Q4 25 | $3.5B | $1.4B | ||
| Q3 25 | $3.7B | $1.4B | ||
| Q2 25 | $3.7B | $1.3B | ||
| Q1 25 | $3.8B | $1.3B | ||
| Q4 24 | $3.8B | $1.3B | ||
| Q3 24 | $3.9B | $1.3B | ||
| Q2 24 | $3.9B | $1.2B | ||
| Q1 24 | $4.2B | $1.2B |
负债/权益比LXPVCYT
| Q4 25 | 0.66× | — | ||
| Q3 25 | 0.72× | — | ||
| Q2 25 | 0.72× | — | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | 0.75× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $188.7M | $52.6M |
| 自由现金流经营现金流 - 资本支出 | — | $48.8M |
| 自由现金流率自由现金流/营收 | — | 34.7% |
| 资本支出强度资本支出/营收 | — | 2.7% |
| 现金转化率经营现金流/净利润 | 6.56× | 1.28× |
| 过去12个月自由现金流最近4个季度 | — | $126.6M |
8季度趋势，按日历期对齐
经营现金流LXPVCYT
| Q4 25 | $188.7M | $52.6M | ||
| Q3 25 | $63.5M | $44.8M | ||
| Q2 25 | $44.3M | $33.6M | ||
| Q1 25 | $39.0M | $5.4M | ||
| Q4 24 | $211.2M | $24.5M | ||
| Q3 24 | $64.6M | $30.0M | ||
| Q2 24 | $38.5M | $29.6M | ||
| Q1 24 | $38.9M | $-9.0M |
自由现金流LXPVCYT
| Q4 25 | — | $48.8M | ||
| Q3 25 | — | $42.0M | ||
| Q2 25 | — | $32.3M | ||
| Q1 25 | — | $3.5M | ||
| Q4 24 | — | $20.4M | ||
| Q3 24 | — | $27.7M | ||
| Q2 24 | — | $26.8M | ||
| Q1 24 | — | $-11.1M |
自由现金流率LXPVCYT
| Q4 25 | — | 34.7% | ||
| Q3 25 | — | 31.8% | ||
| Q2 25 | — | 24.8% | ||
| Q1 25 | — | 3.1% | ||
| Q4 24 | — | 17.2% | ||
| Q3 24 | — | 23.9% | ||
| Q2 24 | — | 23.4% | ||
| Q1 24 | — | -11.5% |
资本支出强度LXPVCYT
| Q4 25 | — | 2.7% | ||
| Q3 25 | — | 2.1% | ||
| Q2 25 | — | 1.0% | ||
| Q1 25 | — | 1.6% | ||
| Q4 24 | — | 3.5% | ||
| Q3 24 | — | 1.9% | ||
| Q2 24 | — | 2.4% | ||
| Q1 24 | — | 2.2% |
现金转化率LXPVCYT
| Q4 25 | 6.56× | 1.28× | ||
| Q3 25 | 1.75× | 2.34× | ||
| Q2 25 | 1.52× | — | ||
| Q1 25 | 2.05× | 0.76× | ||
| Q4 24 | — | 4.80× | ||
| Q3 24 | 10.18× | 1.98× | ||
| Q2 24 | 7.09× | 5.16× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LXP
暂无分部数据
VCYT
| Testing | $135.8M | 97% |
| Products | $3.8M | 3% |
| Biopharmaceutical And Other | $686.0K | 0% |
